Clinical Update (09/2006)

MTI provides an update on bariatric surgery, where a new study which finds that complication rates of patients undergoing obesity surgery are higher than previously thought. Also, MTI reports on a new risk score for dementia.

Although bariatric surgery is helping thousands of people reduce their risk of diabetes and other life-threatening diseases, a new study finds complication rates for patients undergoing obesity surgery is higher than previously thought. The study, sponsored by the Agency for Healthcare Research and Quality, found that four out of every 10 non-elderly patients with private insurance who undergo obesity surgery develop a complication within 6 months of leaving the hospital. The five most common complications were dumping syndrome (nearly 20%), which includes reflux, vomiting, and diarrhea; anastomosis complications (12%), such as leaks or strictures; abdominal hernias (7%); infections (6%); and pneumonia (4%). The study also found that the complication rate increased by 81% following hospital discharge, increasing from 21.9% while patients were still hospitalized to 39.6% by the end of 180 days post-op. Overall, the death rate for the entire 180-day post-operative study period was low, at 0.2%.

Not surprisingly, complications from obesity surgery also increased the overall cost. Medical care spending averaged $36,542 for patients who experienced a complication during their hospital stay and in the 180...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.